⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12496399 | 0.78 | — | — | |
| SCHEMBL24696916 | 0.74 | — | — | |
| SCHEMBL22789410 | 0.74 | — | — | |
| SCHEMBL2065243 | 0.74 | — | — | |
| SCHEMBL26972787 | 0.74 | — | — | |
| SCHEMBL16742787 | 0.70 | PTPN2 (0.31) | — | |
| SCHEMBL7497036 | 0.70 | PTPN2 (0.34) | — | |
| SCHEMBL12913978 | 0.70 | PNMT (0.30) | — | |
| SCHEMBL4164652 | 0.70 | MME (0.32) | — | |
| SCHEMBL6808594 | 0.69 | PGR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299385-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2024-09-12 | — | — | US | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794898-A | 3-pyrrolylsulfonamide compounds as GPR17 antagonists | 瑞文德医疗公众有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254027-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | REWIND THERAPEUTICS NV (BE) | 2022-12-08 | — | — | WO | disclosed |